NVO | Jotup

Appointment of Ms Karen O’Neill as Director

Retrieved on:

Tuesday, March 26, 2024

Audit, NVO, Risk, ASX, Audit risk, TSX, Mining, Management

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) advises that Mr Michael Barrett has resigned as a director of the Company and Ms Karen O’Neill has been appointed as an independent non-executive director of the Company.

Key Points:

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) advises that Mr Michael Barrett has resigned as a director of the Company and Ms Karen O’Neill has been appointed as an independent non-executive director of the Company.
We wish him all the best for future.”
The Company is pleased to announce that Ms Karen O’Neill has been appointed as independent non-executive director to the Board of the Company and will also Chair the Audit, Risk and Corporate Governance Committee.
Ms O’Neill is currently a non-executive director of Great Boulder Resources (ASX:GBR) and has previously served on boards of a number of ASX listed resource companies including Newfield Resources and Kingrose Mining Limited.
Mr Mike Spreadborough said, “On behalf of the Board, we welcome Karen to the Novo team and look forward to her contribution as non-executive director.

Upgraded Nunyerry North Drill Results Deliver High-Grade Intercepts Up to 6.12 g/t Au

Retrieved on:

Tuesday, March 26, 2024

Diamond, Well, NVO, Vein, Gold, ASX, Creasy, RC, Novo, Igneous intrusion, Anomaly, Outline, Estrid, TSX, IP, Aegina, Clutch (eggs), Soil, Rehabilitation, Mining

VANCOUVER, British Columbia, March 26, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce updated, high-grade results from the maiden reverse circulation (RC) drill program completed at Nunnery North in late 2023.

Key Points:

Significant drill intercepts from the 2023 Nunyerry North program of shallow reverse circulation drilling were re-analysed by multi-pot PhotonAssay™.
Commenting on the high-grade results from Nunyerry North, Novo Executive Co-Chairman and Acting CEO Mike Spreadborough said
“It is exciting to see a significant grade increase in the Nunyerry North drill results, some of which are close to surface and demonstrate the substantial upside potential of this Project.
Based on the results, Novo resubmitted all significant drill intercepts for multi-pot PhotonAssay™ whereby all sample material was split over multiple PhotonAssay™ pots.
Figure 3: Nunyerry North geological interpretation, 2023 drill hole location and new drill target areas.

Proposed Board and Leadership Renewal

Retrieved on:

Wednesday, February 28, 2024

Novo, TSX, Growth, Sale, ASX, NVO, Employment, Management

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) has commenced a process of Board and Leadership renewal to position the Company for its next phase of growth.

Key Points:

VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) has commenced a process of Board and Leadership renewal to position the Company for its next phase of growth.
As part of this process, it is also proposed that current Non-executive Co-Chairman, Dr Quinton Hennigh will move to the role of Non-Executive Director.
Finally, as part of the Board refresh strategy, Non-Executive Director Mr Michael Barrett has advised the Company that he will retire from the Board when a suitable replacement director with appropriate finance experience is appointed.
It is anticipated that the Board refresh and leadership transition outlined above will be completed prior to the Company’s Annual General Meeting expected to be scheduled for June 2024.

Significant Drill Results at Becher

Retrieved on:

Tuesday, February 13, 2024

News, Resampling, ALS, Heckmair, Gold, CRMS, Withnell, Anomaly, WNW, ASX, Fault, RC, QAQC, PB, Novo, TSX, Element, NVO, National instrument, WSW, ICP-MS, ICP

VANCOUVER, British Columbia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to provide an update on drilling results at the Becher Project, which is part of the Egina earn-in and joint venture (Egina JV) with De Grey Mining (ASX:DEG).

Key Points:

The Egina Gold Camp is Novo’s highly prospective gold belt in the Pilbara and includes the priority Becher and Nunyerry projects (Figure 1).
No assurance can be given that a similar (or any) commercially viable mineral deposit will be determined at Novo’s Becher Project.
No significant results (>0.1 g/t Au) were returned from AC drilling at Irvine or Bonatti, although RC hole MSRC0030 at Irvine returned 1 m @ 6.3 g/t Au (Appendix 1 – Table 1).
One metre AC drill samples are collected from the drill rig through a cyclone and placed on the ground in piles for geological quantitative and qualitative logging.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on:

Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points:

GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on:

Monday, January 8, 2024

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points:

GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Liatam Mining Investment Closed

Retrieved on:

Friday, December 29, 2023

Quartz, ASX, Gold, TSX, NVO, Mining

VANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that the additional investment by Liatam in Novo of A$1.8 million (approximately C$1.6 million) has closed and the 9,000,000 common shares subscribed for have been issued at a price of A$0.20 (C$0.18) per share, increasing their shareholding from ~3% to ~6%. Liatam has a right to transmute the issued shares into ASX CDIs following expiry of the 4-month hold period to which the purchased shares are subject.

Key Points:

Following this investment by Liatam and the A$10 million transaction with SQM Australia in the Harding Battery Metals JV in the West Pilbara, Novo is in a strong financial position to continue its aggressive exploration focus across key gold targets in the Pilbara, Western Australia and Victoria in 2024.
VANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce that the additional investment by Liatam in Novo of A$1.8 million (approximately C$1.6 million) has closed and the 9,000,000 common shares subscribed for have been issued at a price of A$0.20 (C$0.18) per share, increasing their shareholding from ~3% to ~6%.
Liatam has a right to transmute the issued shares into ASX CDIs following expiry of the 4-month hold period to which the purchased shares are subject.
This investment follows the formation of the Quartz Hill Joint Venture between Novo and Liatam1.

Exploration Status Update

Retrieved on:

Thursday, December 21, 2023

Diamond, ASX, AC, Aboriginal title, Novo, Research, Gold, Geology, RC, TSX, NVO, Mining

VANCOUVER, British Columbia, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to provide an update on current exploration programs and proposed 2024 drilling programs across its Western Australian and Victorian gold portfolio.

Key Points:

Initial two diamond drill holes from ongoing six-hole 2,300 m program completed as planned at Belltopper Gold Project in Victoria.
VANCOUVER, British Columbia, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to provide an update on current exploration programs and proposed 2024 drilling programs across its Western Australian and Victorian gold portfolio.
Balla Balla is an emerging exploration project covering an area over 1,200 sq km, located in the northwestern Pilbara (Figure 4).
Tenement E47/4923 has been recently granted, and overall discussions with Native Title partners are progressing, further enabling access for exploration programs in 2024.

Sale of Nullagine Gold Project to Calidus Resources

Retrieved on:

Wednesday, December 20, 2023

Rehabilitation, ASX, Sale, CAI, Acquisition, NGP, Gold, Calidus, IPO, TSX, NVO, Mining

Calidus has assumed all obligations, royalties, claims and liabilities relating to the Nullagine Gold Project, including the rehabilitation liability.

Key Points:

Calidus has assumed all obligations, royalties, claims and liabilities relating to the Nullagine Gold Project, including the rehabilitation liability.
Novo’s Nullagine Gold Project was a non-core asset and its disposal was foreshadowed in the Company’s ASX IPO prospectus.
The sale of the Nullagine Gold Project is another key step in the Company’s pursuit of identifying and delivering prospective standalone gold projects with +1 Moz development potential.
The sale occurred pursuant to:
an asset sale agreement under which Calidus agreed to acquire additional tenements and assets in the broader Mosquito Creek Basin (from Novo subsidiaries Beatons Creek Gold Pty Ltd, Nullagine Gold Pty Ltd and Rocklea Gold Pty Ltd).

Liatam Mining Makes Investment in Novo and Quartz Hill Joint Venture Formed

Retrieved on:

Wednesday, December 20, 2023

Quartz, Lithium, ASX, Mineral, Gold, Feasibility study, Silver, IPO, TSX, Toronto Stock Exchange, LCT, JV, NVO, Mining

VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO & NVO.WT.A) (OTCQX: NSRPF) is pleased to announce an update to the Quartz Hill Project earn-in agreement with Liatam and also an additional investment by Liatam in Novo of A$1.8 million.

Key Points:

Liatam has exceeded the required spend of A$1.75 million to form the 80%/20% Quartz Hill Joint Venture with Novo in the East Pilbara, Western Australia.
Liatam has acquired legal title to the tenements included in the Quartz Hill Joint Venture and becomes the manager of the joint venture, with Novo retaining 20% ownership of battery mineral rights along with 100% of the gold and silver rights on the tenements.
The Quartz Hill Joint Venture tenements are considered prospective for lithium-caesium-tantalum (LCT) style pegmatite mineralisation.
Following completion of the earn-in requirement, the 80%/20% Quartz Hill Joint Venture (JV) between Liatam and Novo has now been formed.